Four medical societies connect women’s heart health across life stages, making menopause a point to review risk factors and personal history with a clinician.
On October 26, 2026, NBC News reported that the American Heart Association (AHA) and three partner medical organizations had released a coordinated “Female Life Stages” framework for cardiovascular health. The American College of Obstetricians and Gynecologists (ACOG), American Academy of Pediatrics (AAP) and Society for Maternal-Fetal Medicine (SMFM) joined the effort described in three related papers published in Circulation.
The approach being updated is fragmented care rather than a single treatment recommendation. NBC’s reporting describes a system in which different specialties encounter women at different points in life. The framework aims to connect those encounters so that cardiovascular prevention does not become relevant only when a woman is older.
That distinction matters for midlife readers. A menopause appointment and a cardiovascular assessment need not be separate conversations with separate versions of a woman’s history. The framework supports a more connected view of menopause and cardiovascular health, with reproductive milestones informing personalized prevention rather than replacing familiar risk assessment.
NBC’s report and coverage in MedicalXpress describe a shared approach spanning puberty through the years after menopause. Its central contribution is to bring reproductive history into the same picture as cardiovascular measurements and ongoing care.
The reporting describes these stages:
These are broad categories rather than a timetable every woman follows at identical ages. For a reader in midlife, their value is less about finding an exact age bracket and more about understanding which parts of her history belong in current care.
NBC quotes Dr. Natalie Cameron describing possible increases in LDL cholesterol and weight during perimenopause, with blood pressure potentially rising too. The report also discusses changes in sleep and mood during this transition.
The relevant findings are:
These are possible changes, not an inevitable sequence for every woman. The framework also does not establish hormonal change as the sole explanation for midlife shifts in weight, sleep or cardiovascular health.
The practical implication is a review of actual measurements and personal history. A general story about menopause is less useful than understanding whether a particular woman’s results have changed and what those changes mean together.
NBC’s report identifies pregnancy complications such as preeclampsia and gestational diabetes as potential signals of higher cardiovascular risk later in life. That makes pregnancy history relevant beyond the pregnancy itself.
For women who experienced pregnancy-related high blood pressure or gestational diabetes, mentioning that history in later care discussions fits the framework’s prevention-focused approach. The point is continuity: an earlier complication should not become irrelevant simply because the current appointment concerns menopause.
The report also notes an association between menopause before age 45 and higher coronary heart disease risk. Menopause timing therefore belongs alongside other health information when a clinician assesses a woman’s overall risk.
This is where medical history can shape a midlife health discussion. The framework asks clinicians to connect events across time rather than assess the present without that context.
NBC reports AHA figures showing that cardiovascular disease causes more than 400,000 deaths among U.S. women annually. The same reporting says 41% of women recognize cardiovascular disease as their greatest health threat.
Those figures help explain the organizations’ emphasis on earlier recognition. The subject is broader than menopause symptoms and broader than whether a woman currently feels unwell.
NBC and MedicalXpress also report AHA projections that the share of U.S. women with at least one type of cardiovascular disease could rise from 10.7% in 2020 to 14.4% in 2050. Nearly 60% of U.S. women are projected to have high blood pressure by 2050.
These are forecasts rather than certain future outcomes. They provide context for prevention across women’s lives, but they do not establish that menopause alone drives the projected increase. Nor should population figures be read as a prediction of what will happen to an individual woman.
The reporting does not establish one screening timetable, standard laboratory panel or treatment plan for everyone in perimenopause. It also gives no effect size for the reported association between menopause before age 45 and coronary heart disease, so that finding cannot be translated into a personal risk estimate from this coverage.
Individual decisions about testing frequency and medication belong with a qualified clinician who can assess personal history. The useful next step is a focused conversation, not a fixed testing checklist taken from a headline.
The research supports using the menopause transition as an occasion to discuss cardiovascular health. That conversation can bring together blood pressure and cholesterol with blood sugar, sleep and reproductive history.
Questions consistent with the framework include:
These are discussion prompts rather than requests for a predetermined set of tests. They keep the focus on the framework’s stated goals: earlier recognition and personalized prevention.
For someone whose sleep or weight has changed, the conversation can include those concerns without allowing them to crowd out blood pressure or cholesterol. For someone who feels well, the same framework gives preventive care a place in the appointment.
The distinction is between reviewing risk and assuming disease. A transition-related change is a reason for context, not a diagnosis in itself. Refemina’s guide to making health decisions when evidence leaves uncertainty offers a related way to organize questions for a clinical conversation.
Dr. Stacey Rosen, a contributor to the papers and former AHA volunteer president, characterized the approach as a “paradigm shift” in NBC’s reporting. Her point was that cardiovascular health should not become relevant only when women are older.
Dr. Esther Kim described life stages as “windows of opportunity” for prevention and earlier identification of risk. That language captures the framework’s practical value: a transition can create a useful opening for care without being treated as a prediction of illness.
Dr. Sadiya Khan also cautioned against presenting perimenopause as “doom and gloom.” She told NBC that hormonal changes do not mean everyone needs hormone therapy and directed attention toward evaluating traditional cardiovascular risk factors.
That is a specific distinction, not a recommendation against menopause treatment. The cardiovascular conversation concerns a woman’s risk profile; decisions about menopause treatment remain individualized.
The framework points clinical practice toward carrying reproductive history and cardiovascular measurements across specialties, with menopause serving as a timely review point rather than a stand-alone explanation for risk.
Heart-risk changes during menopause need context rather than an automatic product or hormone answer. Refemina’s research-led reporting helps readers navigate conflicting midlife health information by connecting hormonal change with strength and confidence while separating credible evidence from messages that turn every concern into a supplement, hormone or weight-loss opportunity.
Follow Refemina for research-led insights on menopause, strength, metabolism, nutrition, skin, intimacy and confidence through midlife. New articles turn complex topics into clear, useful context.
Keep learning about the changes that shape energy, strength, confidence and wellbeing through midlife.
Explore Resources